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Summary Methionine (MET)-dependent cell lines require MET to proliferate, and homocysteine (HCY) does not act as a substitute for this
requirement. From six O6-methylguanine-DNA methyltransferase (MGMT)-efficient (mer) cell lines tested, two medulloblastomas (Daoy and
D-341) and a lung non-small-cell adenocarcinoma with metastatic potential (H-1623) were most sensitive to MET deprivation, while two
glioblastomas (U-138, D-263) and a small-cell lung carcinoma H-1944 were moderately to weakly dependent. Regardless of the degree of
MET dependence, all of these lines down-regulated their MGMT activity within 48-72 h of transfer from MET+HCY- to MET-HCY+ media, long
before the eradication of the culture. Reduction of MGMT activity was due to a decline of both MGMT mRNA and protein levels. However, the
reduction was not related to the methylation status of the MGMT promoter at the Smal site or the Hpall sites in the body of the gene; such
sites have been shown to be associated in MGMT regulation and in defining the merphenotype. MET-dependent, met tumour cells cultured
in MET-HCY+ were more sensitive to BCNU (IC50 = 5-10gIM) than those cultured in MET+HCY-(IC50 = 45-90 gM), while MET-independent or
mer cell lines were unaffected. This indicates that reduction of MGMT, imposed by the absence of MET, renders mer tumour cells more
susceptible to alkylating agents. The relatively selective suppression of MGMT activity in mer MET-dependent tumour cells, in combination
with the inability of such cells to proliferate in the absence of MET, may lead to the development of more effective treatment strategies for mer
MET-dependent tumours.
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Methionine (MET) is essential for normal growth anddevelopment
of mammals. This amino acid participates in protein synthesis
(Tautt et al, 1982); numerous S-adenosylmethionine-dependent
transmethylation reactions (Stem and Hoffman, 1984); the forma-
tion of polyamines spermidine and spermine (Pegg 1984);
synthesis of cystathionine, cysteine and other metabolites of the
transulphuration pathway; the supply of homocysteine (HCY),
which is needed for metabolism of intracellular folates; and the
catabolism of choline (Finkelstein, 1990). With very few excep-
tions, normal cells can use HCY in place of MET to support all of
the above reactions (Hoffman, 1990; Guo et al, 1993a). In contrast
to normal cells, a large number ofcultured tumour cells and about
25% of fresh human tumours grown in histocultures cannot effec-
tively use HCY in place of MET, and such cells or tumours are
classified as MET-dependent (Guo et al, 1993a,b). There is
substantial evidence that MET dependence occurs more frequently
in metastatic tumour cells (Breillout et al, 1987, 1990; Liteplo,
1990), although reversion of dependence is not necessarily linked
to loss of metastatic potential (Vanhamme and Szpirer, 1989). The
biochemical basis for MET dependency is not yet fully understood.
MET-dependent tumour cells appear to synthesize MET from HCY
by an active MET synthase, but at levels not adequate to both
sustain growth and meet their high transmethylation requirements
(Judde et al, 1989). The most likely biochemical defect leading
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to MET dependency is thought to be related to the synthesis and
availability ofmethylcobalamine, which is directly involved in the
transfer of methyl groups from 5-methyltetrahydrofolate to HCY
(Liteplo et al, 1991; Fiskerstrand et al, 1994).
The defect in the use ofHCY has been extensively investigated
to induce selective killing oftumours while sparing normal tissues.
Lack of MET results in a reversible blockage of rapidly prolifer-
ating tumour cells in the late S and G2 phases of the cell cycle
(Stem and Hoffman, 1986; Guo et al, 1993a). In general, cells
arrested in S, G2 or M are not only susceptible to spontaneous
death, unlike cells arrested in G1, but they are also supersensitive
to various chemotherapeutic drugs, such as doxorubicin, which
blocks and kills in G2 (Stem and Hoffman, 1986). MET-depleting
diets in combination with chemotherapy suppress metastasis of
Yoshida sarcoma and rhabdomyosarcoma tumours in animals
(Breillout et al, 1987; Goseki et al, 1992). Potentiation of many
drugs, some of which act by damaging cellular DNA, indicates
that MET deprivation may compromise DNA repair ability in
addition to causing premitotic cell cycle blocks and cell death in
tumours. The modulation of resistance of tumour cells to
chemotherapy may encompass a large number of mechanisms
including those involved in the processing of the agent (metabo-
lism, conjugation, etc.), its transport into or its elimination from
the target cell, or the reversal or repair of the damage induced by
such agents. A systematic study ofthe modulation ofsuch mecha-
nisms by deprivation ofMET will allow the deployment ofthe full
potential of the MET-dependence phenotype in the treatment of
several tumours. In that context, we examined the effect of MET
depletion on the ability of tumour cells to repair 06-alkylguanine
adducts by 06-methylguanine-DNA methyltransferase (MGMT).
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Such adducts are major contributors to the toxicity of alkylating
anti-tumour agents, such as procarbazine, temozolomide, carmus-
tine and related nitrosoureas commonly used for the treatment of
several tumours (Schold et al, 1989; Dunn et al, 1991; Egyhazi et
al, 1991; Brent et al, 1993; Marathi et al, 1993).
METHODS
Cell culture
NIH/3T3 from American Type Culture Collection (ATCC
Rockville, MD, USA) was used as a negative control for MET
dependence. SWB-40 and U-87, both mer- human anaplastic
glioma cell lines, were used to determine the effect ofMET deple-
tion on BCNU resistance by mechanisms other than those that are
MGMT mediated. The effect of MET deprivation on cell growth
and MGMT levels was examined in Daoy and D-341 (human
medulloblastomas), U-138 and D-263 (human glioblastomas),
H-1994 (a human small-cell lung carcinoma) and H-1623
(a human non-small-cell lung adenocarcinoma with metastatic
ability). The brain tumour cell lines were obtained either from
ATCC (U-138, Daoy, U-87) or were donated by Dr H Friedman
(Department of Pediatrics, Duke University) (D-341, D-263). The
lung tumour cell lines were donated by Dr A Gazdar (Department
ofPathology, UT Southwestem) and were adapted to our medium.
All cells were maintained in culture in Eagle's minimum essential
medium (Gibco) supplemented with lysine, valine and leucine
(100 gM each) and with 10% dialysed MET-free fetal bovine
serum. The medium was also supplemented with non-essential
amino acids (1:100 dilution of stock from Gibco), 1 mm sodium
pyruvate, sodium bicarbonate, 6.0gM a-hydroxycobalamin,
100 jiM folic acid, 0.2 mg ml- gentamicin and either 100 jM L-
MET (MET+HCY-) or200 jM D,L-HCY thiolactone (MET-HCY+).
Cells were plated in MET+HCY- medium and were allowed to
attach and grow until they reached 50% confluency (6 x 106 per
flask). Detaching cells ascertained to be dead by trypan blue exclu-
sion were removed by changing the medium every 48 h. Cells were
then either trypsinized andreseeded in the same medium orwashed
with PBS and supplied with the MET-HCY+ medium. Because of
extensive death in this medium, it was necessary to remove
detaching dead cells on a daily basis. Cells from both media were
harvested at time intervals indicated and used to measure cell cycle
status and MGMT activity. Cells from either cultures (5 x 107)
were also harvested, washed with PBS and immediately frozen as a
source of protein, DNA and RNA. All cells collected were live
(>95%) as determined by trypan blue exclusion.
Staining for DNA analysis
Trypsinized cells were washed with PBS three times and spread on
slides with a cytospin centrifuge at 500 r.p.m. for 1 min. Slides
were dipped in Fix-Rite for 1 min, washed with water and 1 N
hydrochloric acid and incubated in preheated hydrochloric acid at
60°C for 15 min. The slides were rinsed with water, stained with
Schiff's reagent for 45 min at room temperature, treated with two
successive changes offreshly prepared sulphurous acid, rinsed well
and dehydrated. Finally, slides were cover-slipped for DNA
analysis. DNA content was measured by image analysis using a
V-I 470 Optronics camera and Bio-Quant system IV software.
Three to four hundred cells were measured in each slide and the
distribution, based on DNA content, was determined with Lotus
123 software. A control ofnormal lymphocytes was used to assign
DNA content values. MET-dependent cell cycle blocks (MDCCB)
were determined according to Guo etal (1993a) using theequation:
MDCCB = per cent ofGI cells (in MET-HCY+)/per cent ofG,
cells (in MET+HCY-)
where G, is the number of cells in this cell cycle phase and repre-
sented by the cells under the first peak of a DNA-distribution
graph.
MDCCB numbers below one indicate a G2 block, while above
one are consistent withG, blocks.
MGMT activity measurements
Substrate preparation
The [3H]DNA substrate for measurements of MGMT activity was
synthesized as follows: One millicurie of ethanolic solution
of N-[3H]methyl-N-nitrosourea (MNU), having specific activity
18.8 Ci mmol-I (Amersham), was concentrated to 0.2 ml with a
nitrogen stream and mixed with 1 ml of DNA solution (5 mg) in
0.02 M 2-amino-2-methyl-1, 3-propanediol at pH 10. The solution
was incubated for 30 min at 37°C in a water bath and another
30 min at room temperature. DNA was precipitated by adding 10%
(v/v) 2.5 M sodium acetate and three volumes of cold ethanol and
allowed to stand for 18 h at - 20°C. Precipitated DNA was washed
with 70% ethanol (three times) and 100% ethanol (two times) and
redissolved in 3 ml of 10 mM Tris, 1 mim EDTA buffer at pH 7.4.
Substrate characteristics
The [3H]DNA contained 29.8 ,Ci ofradioactivity (alkylation effi-
ciency 3%) which was distributed as 3-methyladenine, 3.5%;
7-MeG, 79.6%; 1-methyladenine, 0.6%; 06-MeG, 9.0%; and other
adducts, 7.3%. The specific activities of7-MeG and 06-MeG were
calculated to be 15.8 ± 0.8 and 16.5 ± 0.5 Ci mmol-I respectively.
For all practical purposes, these were considered equal, although the
specific activity ofthe adducts was only 86% ofthatreported forthe
MNU. Accordingly, the ratio of06-MeG to 7-MeG was 0.113.
Cell extracts
Cells were pelleted at 800 r.p.m. and suspended in five volumes of
100 mM Tris.HCl containing 0.1 mM EDTA and 2 mM DTT with
the pH adjusted to 7.8. Cell suspensions were freeze-thawed three
times using liquid nitrogen and sonicated for 10 s (three times)
using 70% maximum output. A small aliquot was removed for
DNA determination. Cell debris was removed by spinning at
18 000 g for 10 min at 0°C and the supematant removed and
frozen in liquid nitrogen until used. Protein was determined by the
method ofBradford 1976).
MGMTassay
[3H]DNA dissolved in 100 mm Tris, 0.1 mM EDTA, 2 mM DTT at
pH 7.8 and containing 60 fmol of 06-MeG (total d.p.m. 24 x 103)
was incubated with 0-500 gg of protein (depending on suspected
MGMT activity) for 1 h at 37°C in a final volume of 500 tl. The
reaction was quenched with 0.1 ml of 1 N HCI, and samples were
incubated for an additional 45 min at 70°C. Samples were cooled
on ice for 1 h, centrifuged at 14 000 g for 5 min, the supematant
removed and neutralized with sodium bicarbonate, and dried by
lyophilization. Lyophilized samples were dissolved in 0.12 ml
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0.1 M HCl, spun at 14 000 g and analysed by HPLC using a
Supelcosil-C18DB analytical column (Supelco). Samples were
eluted at a flow rate of 1.5 ml min-' with 2% acetonitrile in 0.1 M
phosphate buffer pH 3.5 (0-5 min) followed by a gradient of 1%
acetonitrile per min (5-15 min). Radioactivity was monitored
by fraction collection and scintillation counting. The 7-MeG and
06-MeG were eluted at 4.5 and 13 min respectively. The ratio of
radioactivity under the 06-MeG over that of 7-MeG from four
samples of varying protein concentration was derived and plotted
against the amount of protein. The intercept of the central linear
response of the curve (between ratios 0.9 and 0.3) with the x-axis
marks the amount ofprotein needed to remove 60 fmol of06-MeG
from DNA. The assay is sensitive enough to detect MGMT levels
as low as 5 fmol mg-' protein with an error ofless than 10%.
SDS-polyacrylamide gel electrophoresis and
immunoblotting
Proteins were resolved in a Bio-Rad (Richmond, CA, USA) mini-
gel apparatus at 200 V for 45 min on 0.75 mm SDS-PAGE slab
gels using the method ofLaemmli (1970). The gels were calibrated
with Bio-Rad low molecular weight standards. Proteins were
transferred onto PVDF membrane (Immobilon-P, Millipore,
Bedford, MA, USA) by the method of Matsudaira (1987) using a
Bio-Rad Mini trans-Blot cell for 2 h at 140 mA. Blots were
blocked with 5% bovine serum albumin (BSA) in 20 mm Tris pH
8.2 with 0.9% sodium chloride and were probed for 2 h with
mouse monoclonal antibody MT3.1 specific for human MGMT in
a buffer containing 20 mm Tris pH 8.2 0.1% BSA, 0.9% sodium
chloride, 1% normal goat serum and 5% concentrated gelatin solu-
tion (Amersham). Antibody binding was visualized with
Amersham's gold-labelled secondary antibody and silverenhance-
ment using Auroprobe and IntenSE reagents (Amersham),
according to manufacturer's instructions. The intensities of bands
were quantitated in a photographic positive by whole band
analysis on a Bio-Image Visage 110 analytical imaging instrument
(Millipore).
DNA probes
MGMT cDNA was derived by polymerase chain reaction (PCR)
ofthe cloned insert in the plasmid pKT100 (Tano et al, 1990) using
#1201 and #1211 sequencing primers (New England Biolabs,
Beverly, MA, USA) with a GeneAmp kit (Perkin Elmer Cetus,
Norwalk, CT, USA) using the starting parameters recommended
by the manufacture. Twenty-five cycles of amplification were
carried out, with each cycle consisting of 30 s at 94°C, 1 min at
45°C and 1 min at 72°C. A 772-bp sequence from the MGMT
promoter was obtained by restriction of the plasmid pKT200
(Harris et al, 1991) with Sstl (Gibco-BRL, Gaithersburg, MD,
USA) and Pstl (New England Biolabs) and excision of the frag-
ment from low-melting point agarose gel.
Northern Analysis
Total RNA was prepared from frozen cells by lysing them in
RNAzol (Tel-Test, Friendswood, TX, USA) according to the
manufacturer's protocol. RNA (10 jg) was size fractionated in 1%
agarose gels containing 2.2 M formaldehyde (Fisher, Fair Lawn,
NJ, USA) (Sambrook et al, 1989) and transferred to nylon
membranes (Duralon-UV, Stratagene, La Jolla, CA, USA) by
capillary blotting. RNA was covalently attached with UV and
prehybridized for 4 h at 42°C in 50% formamide, 5 x SSPE
(0.18 M sodium chloride, 0.01 M sodium phosphate, 1 mm EDTA),
5 x Denhardt's solution (Sambrook et al, 1989), 7.5% dextran
sulphate, 1.5% sodium dodecyl sulphate (SDS), and 200jg ml-' of
sheared salmon sperm DNA. Hybridization was conducted with
32P-labelled MGMT cDNA probe for20 h at42°C. Unbound probe
was removed by washing membranes twice with 200 ml of
2 x SSC (0.015 M sodium chloride, 0.0015 M sodium citrate) for
15 min at room temperature, followed by washing twice with 200
ml of0.1 x SSC, 0.1% SDS for 15 min at 65°C. Membranes were
exposed to X-Omat AR Kodak film at-70°C, and RNA was quan-
titated. Membranes were reprobed with GAPDH cDNA (Clontech,
Palo Alto, CA, USA) to control for equal loading and transfer.
After this hybridization, membranes were washed as before except
that the final step was performed at 68°C instead of65°C.
Analysis of MGMT gene methylation
Ten micrograms of genomic DNA from each cell line, isolated
according to protocol 1 of Sambrook et al (1989) was restricted
with S U jig-' of EcoRI and HpaII (New England Biolabs) for
4-6 h and then restricted again with the same amount of enzyme
overnight. Electrophoresis of the samples in a 0.7% agarose gel
containing 0.5 x TBE at 22 V for 18 h was followed by alkaline
denaturation and neutralization, according to Sambrook et al
(1989), and capillary blotting onto a nylon membrane as in
Northern analysis and covalent linking of the DNA using UV
light. The blot was hybridized with a 32P-labelled MGMT cDNA
probe and washed as described for Northern analysis before
autoradiography for 2 days at-70°C with intensifying screens.
Analysis of MGMT promoter methylation
Methylation ofthe 5'-untranslated region of the MGMT gene was
investigated by Southern analysis using the methylation-sensitive
restriction enzyme SmaI (Promega, Madison, WI, USA). Genomic
DNA was restricted with 5 U jg-I of enzyme at 37°C (25°C for
SmaI) for 4-6 h and then restricted again with the same amount of
enzyme overnight. Southern analysis was performed using the
772-bp probe from the 5'-untranslated region.
Cytotoxicity assays
The cytotoxicity of BCNU on cultured cells in MET+HCY- and
MET-HCY+ was measured by a modification of the method of
Branch et al (1993) as follows: MET-dependent cells were seeded
and cultured in MET+HCY- in 35-mm Petri dishes until they were
nearly confluent. The cells were then transferred in MET-HCY+
and cultured for an additional 4-6 days at which time cell numbers
were reduced because ofcell death and inhibition ofmitosis. Dead
cells were removed and medium was replaced on a daily basis.
Following this period in MET-HCY+ medium, remaining live cells
were washed with PBS and then treated with various concentra-
tions of BCNU in PBS for 1 h at 37°C while they were still
attached. Subsequently, the' BCNU was removed, replaced with
MET+HCY- medium, and cultures were incubated for an addi-
tional 4 days at 37°C in 6% carbon dioxide. At that time cells were
trypsinized and counted using a Coulter-Counter (Coulter
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Electronics, Hialeah, FI, USA). The concentration of the drug that
halves the growth rate of the tumour cells (IC50) was determined
from plots of BCNU concentrations vs the per cent change in cell
numbers compared with untreated controls within a 4-day interval
from treatment (Jackson, 1992). The IC50 of BCNU on MET-
dependent cells cultured in MET+HCY- or MET-independent cells
cultured in either media was also determined by the same method.
With such cultures, however, cell numbers originally seeded were
adjusted to yield cell densities that were similar to those of
MET-HCY+ cultures at the time of treatment with BCNU.
RESULTS
Inhibition of cell proliferation by methionine withdrawal
Doubling times for MET-dependent, mer+ Daoy, D-341, U-138,
D-263, H-1944 and H-1623 in MET+HCY- were estimated from
cell counting as 26, 34, 45, 42, 56 and 46 h respectively. Doubling
times for mer- U-87 and SWB-40 tumour cells and NIH-3T3 were
45, 32 and 26 h respectively. Figure 1 shows that, with the excep-
tion ofU-87 which continued to proliferate in MET-HCY+, the rest
of the tumour lines tested were MET dependent. This was best
demonstrated with Daoy, H-1623 and D-341 which were nearly
eliminated 6 days following their transfer from the MET+HCY- to
MET-HCY+ medium. A less rapid or extensive reduction in cell
populations within the same time period was also observed in
U-138, SWB-40, D-263 and H-1944 cultures in MET-HCY+. After
this initial cell loss, further decline of populations was observed in
all tumour cell lines, although at a slower rate. The biphasic rates
160
140
120
180
2)
0 80
(D
60A
407
20
0'
0 2 4 6 8 10 12 14
Days in MET-HCY+
Figure 1 Effect of replacement of methionine with homocysteine on cultures
of the Daoy (o), D-341 (@), U-138 (7), D-263 (V), H-1944 (A\), H-1623 (A),
U-87 (E1). SWB-40 (m) and NIH-3T3 (*). Cells growing exponentially in
MET+HCY- were washed with PBS two times and seeded in MET-HCY+
medium. Cultures were trypsinized, and live cells, as determined by trypan
blue exclusion, were counted
of cell loss in MET-HCY+ cultures was indicative of at least two
different mechanisms of toxicity. Examination of cell cycle
kinetics indicated the accumulation in late S and G2 at day 2 from
transfer to MET-deficient media (Figure 2), which was character-
istic ofa G2 cell cycle block. Cell cycle kinetic analysis for the Daoy,
U-138, H-1632 and D-341 is shown in Table 1. MET-dependent G2
cell cycle blocks (MDCCB<0.8) were observed in all of these four
lines, but they were not detectable in H-1944, SWB-40 and D-263,
which were moderately to weakly dependent on MET. A G2 block
was imposed earlier in H-1623, D-341 and Daoy than in U-138
and was generally followed by a massive detachment and death of
cells (Figure 1) and a concomitant increase of the MDCCB
(Table 1). Following the G2 block and elimination of G2-arrested
cells, the mitotic index declined rapidly by more than an order of
magnitude below the control value as the MDCCB number
increased above one, indicating that surviving cells did not cycle
and were most probably checked at G,. MDCCB fluctuations
consistent with G2 or GI blocks were not found in NIH-3T3 or
U-87 which were not MET dependent and proliferated in
MET-HCY+. Cell cultures of MET-dependent cells tested here
could be rescued, even after elimination of more than 95% of the
original cell population, by replenishing MET in the medium.
Karyotypic analysis before MET depletion, and also 48 h after the
repletion ofMET in a Daoy culture deprived of MET for ten days,
indicated that no additional chromosomal aberrations or selection
of a resistant cell population were introduced by this treatment. In
all cell lines tested, repletion ofMET in the medium resulted in the
recovery of both cell proliferation capacity and base line MGMT
activity. In Daoy, recovery of the MGMT activity was not
complete 48 h (65% of the base line) from repletion of MET
following a 10-day culture period in HCY (DM Kokkinakis,
unpublished observations). At that time cells had recovered their
ability to divide and proliferated with a doubling time of 22 h.
Reduction of MGMT activity in tumour cells by
methionine depletion
The native MGMT activities of the cell lines tested here are shown
in Table 2. These activities were not affected by serum withdrawal
and the associated inhibition of growth for up to 72 h, and they
were not dependent on the state of confluency of the culture (data
not shown). A cell cycle-dependent regulation of MGMT activity,
previously suggested (Dunn et al, 1986) by serum starvation
synchronization, was also not evident in these lines. However,
MGMT activities were dependent on the presence of MET in the
culture medium (Table 2). With the exception of NIH-3T3 cells,
which were not MET dependent, MGMT activity declined with a
half-life ranging from 24 to 48 h after cells were transferred to
MET-HCY+ media and reached a nadir of25-40 fmol mg-' protein
in all the lines tested. Levels of MGMT activity remained low in
MET-dependent cells as long as such cells remained alive in the
MET-HCY+ medium. In Daoy, the decline in the MGMT activity in
MET-HCY+ was due to the reduction ofMGMT protein (Figure 3).
The amount ofMGMT protein determined by densitometric scan-
ning 6 days after culturing in MET-HCY+ was reduced eightfold,
which was similar to the decline of MGMT activity. Northern
analysis (Figure 4) indicated that the reduction of the protein and
activity was reflected by a similar reduction of mRNA without
notable reduction ofmRNA for GAPDH, another 'housekeeping'
protein. Reduction of the MGMT mRNA was notable 48 h after
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Figure 2 Effect of replacement of methionine with homocysteine on the distribution of cell populations of Daoy in G1, S and G2compartments. Cell cycle distribution
in MET+HCY- (A) and MET-HCY+ after 2 (B), 4 (C) and 6 (D) days of culture. A G2 block results in a shift of distribution from G1 to G2 as early as day 2
transfer to MET-HCY+ medium and further declined to levels that
were barely detectable a week after MET deprivation. The above
suggests that MET deprivation affects MGMT transcription or
mRNA stability and probably not MGMT protein translation or
stability. Down-regulation of MGMT expression by MET depriva-
tion could be theoretically related to changes in methylation ofcyto-
sine in key positions ofthe MGMT gene and promoterbecause ofthe
decline of the capacity ofcells to transmethylate when cultured in a
HCY medium. Recent studies have shown that cytosine methylation
influences MGMT gene expression (von Wronski et al, 1992; Wang
et al, 1992; Costello et al, 1994). Methylation of the MGMT
promoter is associated with loss of gene expression, while methyla-
tion ofthe gene itself appears to enhance its expression. Specifically
methylation in theSmaI restriction site (-69) ofthe MGMT promoter
has been found only in mer- tumour cell lines (von Wronski et al,
1992). On the other hand, 5-azacytidine induced methylation of the
body of the gene at HpaH-sensitive sites results in a substantial
increase of the MGMT activity in some tumour cell lines (von
Wronski and Brent, 1994). Surprisingly, decline of mRNA induced
by MET withdrawal was not associated with changes in the methyla-
tion status of the MGMT promoter or the body of the gene at the
SmaI and Hpall sites respectively (Figure 5). In Daoy, the SmaI site
at -69 was entirely unmethylated in both the control (MET+HCY-)
and down-regulated cells (MET-HCY+), which is consistent with the
observation that this line remains mer+ even in the absence ofMET.
Lack of an effect ofMETdeprivation on the methylation ofthe SmaI
and Hpal sites was also observed in the mer-, MET-dependent
U-138 (data not shown).
Potentiation of the toxicity of nitrosoureas by
methionine depletion
The mer+ Daoy line was resistant to BCNU in MET+HCY- with an
IC50 of45 gM. Such resistance was compromised and the IC50 was
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Table 1 Variation of MDCCBa and mitotic activity after transfer of MET-
dependent tumour cell cultures to MET-HCY+ medium
Cell line Time (days) MDCCB Mitotic index % of controlb
DAOY 1 0.70±0.1Oc 51 ±6c
2 0.45+0.11 24±4
3 0.89±0.08 12±4
4 1.10±0.06 3±2
5 1.62±0.11 0
6 1.68±0.13 0
U-138 2 0.85 ±0.09 38± 11
4 0.61 +0.08 21 ±7
6 0.99±0.12 6±3
8 1.05±0.09 0
10 1.45+0.09 0
H-1623 1 0.42 ± 0.06 27 ±5
2 0.88+0.04 13±3
4 1.35±0.12 5±2
6 1.57±0.11 0
D-341 1 0.66 ± 0.08 49± 11
2 0.45+0.06 12±4
4 0.89 ±0.09 0
6 1.06+0.11 0
8 1.31±0.12 0
a MDCCB, MET-dependent cell cycle blocks. Numbers < 1.0 show
accumulation of cells in G2, while >1 demonstrate a G1 block. b Mitotic indices
(mitosis per 1000 cells) for Daoy, U-138, H-1623 and D-341 in MET+HCY-
were 49, 39, 52 and 67 respectively. c Mean of three experiments ± standard
deviation.
Table 2 Time dependence of MGMT activity in MET-HCY+ cultures
Cell line Timea MGMTb Cell line Timea MGMTb
DAOY 0 383 ± 410 H-1623 0 880 ± 51
2 85±9 2 326±62
4 61±5 4 132±9
6 32+4 6 51±13
8 35+3 8 41±12
10 33±5
U-138 0 384 + 35 H-1944 0 328+ 11
2 140 ± 13 2 263±28
4 85±9 4 143±17
6 33+4 6 75±5
8 21±4 8 48±5
10 25±3 10 42±5
D-341 0 361± 18 NIH3T3 0 236 ±33
2 139 + 15 2 287 ± 18
4 63±8 4 285±32
6 35±4 6 291 ±43
8 33+4 8 311 ±58
aDays after replacing MET+HCY- with MET-HCY+ medium. bf mol mg-'
protein. cStandard deviation from three determinations.
reduced to approximately 5 ,UM when cells were cultured in
MET-HCY+ for4 days before the exposure to BCNU (Figure 6A).
In comparison, the resistance of the mer-, MET-dependent SWB-
40 to BCNU was not affected by MET depletion (Figure 6B). The
similar response of mer+ Daoy and mer- SWB-40 to BCNU in
kDa
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Figure 3 Immunoblot analysis of MGMT protein in Daoy cell line cultured in
either MET+HCY- (M) or in MET-HCY+ (H) media. Twenty micrograms of
extract protein was electrophoresed in a 12% SDS-polyacrylamide gel.
Proteins were electroblotted onto a PVDF membrane which was probed with
monoclonal antibody MT3. 1 specific for human MGMT. MGMT in the human
leukaemic lymphoblast line CEM-CCRF is shown as control
MET-HCY+ and the demonstrated association between BCNU
sensitivity and MGMT activity in Daoy suggests that this line
owes its resistance to alkylating agents to the high levels of
MGMT reserves. On the other hand, the marginal effect of MET
deprivation on the resistance of SWB-40 to BCNU suggests that
down-regulation ofMGMT activity is probably the majorpathway
for the loss ofresistance to BCNU and to related alkylating agents
in association with the MET-dependence phenotype. An extensive
correlation between the down-regulation of MGMT activity by
methionine deprivation and the sensitization to BCNU was demon-
strated with several mer-, MET-dependent cell lines (Table 3).
DISCUSSION
Tumours have high MET requirements because of accelerated
protein synthesis and transmethylation reactions to yield S-adeno-
sylmethionine, serine, sarcosine, glycine and various phospho-
lipids (Mineura et al, 1993; Kubota et al, 1995). Twenty-five
per cent of human tumours are estimated to be absolutely depen-
dent of MET and cannot use HCY to either proliferate or
survive (Guo, 1993). A greater percentage is expected to be
moderately to weakly dependent on MET and to respond, to some
extent, to MET deprivation (Hoshiya et al, 1995). In this regard
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Figure 4 Northern analysis of MGMT mRNA expression in Daoy cultured in
either MET+HCY- (M) or in MET-HCY+ (H). Twenty micrograms of total RNA
from a MET+HCY- culture and from cultures deprived of MET (MET-HCY+) for
2, 4 or 7/8 days respectively were subjected to electrophoresis, transferred to
a nylon membrane and probed with 32P-labelled human MGMT cDNA (top).
Reprobing the membrane with 32P-labelled GAPDH cDNA (bottom)
demonstrates similar loading for all samples. Lanes 1-4 and 5-8 represent
duplicate Northern analyses
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Figure 5 Southern analysis of methylation sensitive restriction sites in the
MGMT gene in Daoy cultured in either MET+HCY- (M) or in MET-HCY+ (H).
Ten micrograms of DNA from each culture was either restricted with Sacd
and Smal and probed with the 772-bp MGMT promoterfragment (A) or with
EcoRI and Hpall and probed with MGMT cDNA (B). METdeprivation has no
effect on cystosine methylation in either the MGMT promoter (Smal, -69
site) or in the body ofthe gene
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Figure 6 Effect of methionine depletion on the sensitivity of the merSWB-40 (A) and the mer Daoy (B) cell lines to BCNU. Cells previously cultured in
MET+HCY- (o) or in MET-HCY+ (@) for 4 (Daoy) or 6 (SWB-40) days were exposed to BCNU for 1 h at 370C and subsequently cultured in MET+HCY- medium.
Live cell populations were determined at day 4 after BCNU treatment in expanding cultures and plotted against BCNU concentrations. Cell numbers were
compared with those of their respective control (no BCNU) to determine BCNU-induced growth inhibition and death
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Table 3 Sensitization of MET-dependent tumour cells to BCNU by MET
withdrawal
Cell line Remaining MGMTa IC50 (MET)b IC50 (HCY)
Daoy 8.6 45 5
U-138 6.5 50 10
D-341 9.1 65 10
H-1623 4.6 90 10
H-1944 12.8 65 10
U-87c ND 15 15
SW-40c ND 10 15
NlH-3T3d 131.8 35 40
aPer cent MGMT activity remaining after exhaustive deprivation of exogenous
MET. bConcentration (,UM) of BCNU needed to reduce relative survival by
50%, 4 days following 1-h incubation with the drug. cmer lines, not detectable
(ND) MGMT. dControl merF, MET-independent cell line.
MET deprivation is an interesting approach to therapy ofa variety
of tumours assuming that reduction of plasma methionine below
the threshold needed to suppress cell proliferation in the tumour
can be achieved. As the exogenous MET requirement of MET-
dependent tumour cell lines varies (Halpern et al, 1974; Hoffman
and Erbe 1976; Breillout et al, 1987), the behaviour oftumours in
vivo, where MET cannot be completely eliminated, is difficult to
predict. Prolonged reduction of plasma MET can be non-toxic in
animals if HCY is supplemented to supply normal tissues with a
MET precursor. Thus, an eighty percent reduction ofplasma MET
has been obtained in athymic mice fed a MET-free diet. Further
reduction (approximately 95%) can be achieved with the use ofL-
methionine-a-deamino-y-mercaptomethane lyase, also known as
methioninase (Lishko et al, 1993), an enzyme that has been
recently cloned and mass produced (Hori et al, 1996). A combina-
tion of MET-depleting diets and methioninase could theoretically
cause a decrease in plasma MET to less than 5 gM, which is the
threshold for supporting cell proliferation in all MET-dependent
tumour cell cultures examined (DM Kokkinakis, unpublished
observations).
Three out of eight tumours tested here are strongly dependent
on MET and are rapidly and nearly eradicated, mainly as the result
ofG2 blocks induced by MET deprivation. The rest ofthe tumours
tested, including all gliomas, resisted MET starvation (in the pres-
ence of HCY) and were able to survive for several weeks and
resume growth when MET was repleated. Prolonged survival,
possibly as the result of G, cell cycle blocks of MET-dependent
tumour cells is expected to be a major problem in any effort to
eradicate tumours based entirely on MET-depleting regimens. In
this regard, although MET depletion may be useful in replacing
toxic chemotherapeutic treatments, its greater application could be
in conjunction with currently used chemotherapeutic agents, as
previously suggested (Stem and Hoffman, 1986; Breillout et al,
1987; Goseki et al, 1992).
A major mechanism of resistance of cells to genotoxic injury,
particularly to the formation ofthe toxic and mutagenic 06-alkyl-
guanine DNA adducts and to subsequent lethal DNA cross-links,
is mediated by the DNA repair protein MGMT. This protein,
which reverses formation of 06-alkylguanine adducts including
those with the potential to react with DNA bases of the opposite
strand and form cross-links, is abundant in more than eighty per
cent ofthe human tumours, rendering them resistant to a variety of
genotoxic alkylating chemotherapeutic agents (Day et al, 1980;
Tsujimura et al, 1987; Dolan et al, 1990). In many cases, levels of
MGMT activity in tumour tissue are well above that ofthe normal
surrounding tissue or of other vital tissues (Gerson et al, 1985).
This is believed to be the main reason for the poor therapeutic
index ofmany chemotherapeutic genotoxic drugs that alkylate the
06-position ofguanine used in chemotherapy. Significant increase
in the efficacy of alkylating chemotherapeutic drugs, such as
BCNU, against MGMT-positive tumours has been obtained with
the prior depletion of MGMT activity both in tumour and in
normal tissue by O6-benzylguanine and its analogues (Dolan et al,
1993; Schold et al, 1996). Depletion ofMGMT in animals treated
with 06-benzylguanine analogues is effective provided that the
inhibitor and its active metabolites are present in adequate concen-
trations to sustain destruction of newly synthesized MGMT
(Kokkinakis et al, 1996). As MGMT inhibitors inactivate only
existing protein and have no effect on the transcription or transla-
tion ofthe stable MGMT message, MGMT activity appears imme-
diately after clearance of the inhibitor owing to continuous
translation ofpersisting MGMT mRNA. An even greater increase
in the efficacy of BCNU, and similar genotoxic drugs that kill
primarily because of06-alkylguanine adducts, can be achieved by
depleting both the MGMT protein and its mRNA only in the
tumour while leaving normal tissues unaffected. Theoretically, this
can be accomplished in tumours that possess both the MET depen-
dent and mer+ phenotypes by MET-depleting regimens.
Selective depletion of both the MGMT protein and its mRNA
can be imposed on tumour cells by MET deprivation. Depletion
of the activity and most probably of the protein in Daoy, U-138,
D-341 and H-1623 follows first-order kinetics with half-lives
varying between 36 and 48 h. In H-1994 and D-263, which are
weakly dependent on MET, a lag period of approximately 48 h
precedes such decline ofactivity. The detection ofMGMT mRNA
in Daoy, 8 days after MET withdrawal, suggests that transcription
of the MGMT gene is not completely silenced in a MET-depleted
state. Persistence ofMGMT mRNA for that length oftime without
new synthesis is unlikely in spite of the reported stability of
the MGMT message in several tumour cells lines (Kroes and
Erickson, 1995). Low levels of MGMT found in MET-HCY+ for
several days after reaching a nadir further demonstrate the slow
rate ofbasal transcription ofthis gene by cells that are apparently
blocked in G,. In the simplest scenario, MET withdrawal inhibits
transcription but has no effect on the stability of mRNA and
protein. A gradually declining MGMT activity therefore reflects
the difference between degradation of the protein with a half-life
of approximately 20 h (Brent et al, 1991) and translation of pre-
existing mRNA, which is also on a decline, with a half-life of
approximately 12 h (Kroes and Erickson, 1995). Resynthesis of
protein, mainly from translation ofpre-existing mRNA, may influ-
ence the kinetics of MGMT decline by increasing the apparent
half-lives ofthe MGMT activity from the expected 20 h up to 48 h
depending on the tumour line. A lag period in the decline of
MGMT activity observed in H-1944 is probably the result of the
ability of this cell line to use HCY and maintain higher levels of
endogenous MET than Daoy (data not shown). The mechanism of
down-regulation of MGMT activity by MET deprivation could
potentially involve changes in the methylation of the gene. Such
changes, particularly at the promoter region of the MGMT gene,
have already been recognized as having an intimate association
with cellular levels in MGMT activity. Thus, a direct correlation
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between methylation in the body of the gene and MGMT expres-
sion has been previously observed (Pieper et al, 1991; Harris et al,
1994; von Wronski and Brent, 1994), whereas methylation at the
5' promotor region has been associated with complete suppression
of the gene (von Wronski et al, 1992; von Wronski and Brent,
1994). Consistent with the latter correlation, cells expressing high
levels of MGMT, such as Daoy and U-138, are not methylated at
the SmaI site ofthe promoter. It is not surprising that the SmaI site
remained methylation free under conditions of MET deprivation,
although such methylation would be consistent with the observed
MGMT suppression. It is still possible that methylation of the
promoter region at other sites could be involved in transcriptional
suppression as a number of sites with such potential have been
identified in tumour cells (Qian et al, 1995). However, regulation
of MGMT activity by hypermethylation of the promoter is not
expected to occur in a MET-deficient state, especially in the pres-
ence ofhigh levels ofHCY which could result in the accumulation
of S-adenosylhomocysteine and consequently in the inhibition of
DNA methylation and other transmethylation reactions (Johnson
and Aswad, 1993). If MET deprivation regulates MGMT activity
by changing the methylation status of the gene, it would be
expected that such regulation would be the result ofthe hypomethy-
lation of the downstream region rather than the methylation of the
promoter. The absence ofchanges in the methylation ofthe body of
the gene indicates that either methylation is not involved in the
down-regulation ofMGMT by MET deprivation, or changes ofthe
status of methylation are not detected by the methodology used. If
methylation of CpG islands is not involved in the down-regulation
of MGMT activity in MET-dependent tumours by MET depriva-
tion, it may be because of changes in chromatin structure or trans-
acting factors by mechanisms not yet identified.
The down-regulation of MGMT by MET deprivation in mer+,
MET-dependent tumour cells indicates that MET-dependent
tumours are susceptible to MET deprivation not only because of
cell cycle blocks, but also because they are sensitized to alkylating
agents. Our results indicate that the reduction ofMGMT activity is
not strictly dependent on the degree ofsensitivity ofthe tumour to
MET deprivation. Tumour cells that are moderately MET depen-
dent and resist MET withdrawal, such as U-138, lose their MGMT
activity nearly as fast as fully MET-dependent lines, such as the H-
1623 and Daoy. This is particularly important in vivo where MET
levels cannot be indefinitely suppressed to near zero levels. Thus,
MET-depleting regimens, dietary or enzymatic, could be used to
arrest or reverse tumour growth long enough to suppress MGMT
activity. Elimination ofa substantial portion ofthe tumour mass as
a result ofG2 blocks may facilitate further treatment ofthe tumour,
but it is not an absolute requirement for the employment ofchemo-
therapy aiming to kill cells sensitized to DNA damage. Additional
mechanisms ofresistance may also have been compromised by the
lack of MET, which could explain the reported susceptibility of
MET-dependent cells to the combination of MET depletion with
antineoplastic drugs other than alkylating agents. These results
further support the use ofMET depletion regimens in combination
with genotoxic drugs for the treatment of MET-dependent, mer+
tumours.
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ABBREVIATIONS
MGMT, 06 methylguanine-DNA methyltransferase; 06-MeGua,
06-methylguanine; 7-MeGua, 7-methylguanine; MET, methio-
nine; HCY, homocysteine; DTT, 1, 4-dithiothreitol; BSA bovine
serum albumin; mer+l-, MGMT expressing/deficient; GAPDH,
glyceraldehyde-3-phosphate dehydrogerase
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